Brian Clevinger
Founder & Managing Director @ Prolog Ventures
St Louis, United States
Brian Clevinger is a seed investor at Prolog Ventures in St Louis focused on Biotechnology and Genetics. Brian is Co-Founder and General Partner of the Yield Lab Europe and led efforts on behalf of Yield Lab USA to come to Ireland. He is also Co-Founder and Managing Partner of Prolog Ventures, an early stage venture capital fund in the healthy living space, which includes agriculture, food and animal health.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Brian Clevinger invests in
Stages Brian Clevinger invests in
Countries Brian Clevinger invests in
Investment Focus
Industry
- Biotechnology 2 (29%)
- Genetics 1 (14%)
- Health Care 1 (14%)
- Medical Device 1 (14%)
- Intellectual Property 1 (14%)
Stage
- Seed 1 (14%)
- Series A 1 (14%)
- Series D 1 (14%)
- Series E 1 (14%)
- Funding Round 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Agribody Technologies, Inc.
|
Agribody Technologies is a agricultural biotechnology company with patented technology that pinpoints and knocks down the gene that causes quick decay in perishable crops, resulting in 3X - 4X longer shelf life, more tolerance to stress, and up to 40% higher yields. CRISPR genome editing is the technical breakthrough enabling our precise novelplant trait development at low cost and high scalability, providing solutions for agricultural crop loss and food waste. We license and co-develop our technology. | $1.6M / Seed / Dec 25, 2017 | |
AirXpanders
|
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $1M / Series E / Sep 03, 2014 | |
|
AirXpanders
|
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $9M / Series E / Jun 03, 2013 | |
|
AirXpanders
|
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $11M / Series D / Apr 20, 2012 | |
|
AirXpanders
|
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $10.3M / Series D / Jan 23, 2012 | |
|
AirXpanders
|
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $5.6M / Series A / Jan 22, 2007 | |
|
AirXpanders
|
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant. | $4M / Dec 29, 2006 |
Co-Investors
About Prolog Ventures
Prolog backs companies that help all of us enjoy healthy lives in a healthy world
Prolog Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Greg Johnson
Founder & Managing Director
|
|||
Ilya Nykin
Co-founder & Managing Director
|
|||
|
Brian Clevinger
Founder & Managing Director
|
|||
Courtney Harris
Controller
|
|||
Dan Broderick
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Brian Clevinger invest in?
Brian Clevinger invests primarily in Biotechnology, Genetics and Health Care startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Brian Clevinger last invest?
The most recent investment recorded for Brian Clevinger closed in Dec 2017. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
